Long-term efficacy of intravenous pamidronate in Paget's disease of bone
Related Experiment Videos
A Grauer1, B Klar, S H Scharla
1Department of Internal Medicine I, University of Heidelberg, Germany.
Seminars in Arthritis and Rheumatism
|February 1, 1994
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Association between telemedicine use and diabetes risk factor assessment and control in a primary care network.
Journal of endocrinological investigation·2022
A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Determinants of imminent fracture risk in postmenopausal women with osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019
Risk of subsequent fracture after prior fracture among older women.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2018
Predictors of near-term fracture in osteoporotic women aged ≥65 years, based on data from the study of osteoporotic fractures.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Predictors of response and long-term efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study.
Seminars in arthritis and rheumatism·2026
Evidence-informed exercise dose targets for rheumatoid arthritis: A systematic review and bayesian dose-response network meta-analysis.
Seminars in arthritis and rheumatism·2026
Incidence and characteristics of cytokine release syndrome in patients with systemic sclerosis undergoing autologous haematopoietic stem cell transplantation.
Seminars in arthritis and rheumatism·2026
Evolution of outcome assessment in clinical trials of rheumatoid arthritis: A scoping review.
Seminars in arthritis and rheumatism·2026
Association of antenatal glucocorticoids with risk of autoimmune diseases in children: a nationwide cohort study.
Seminars in arthritis and rheumatism·2026
Pharmacy-based naloxone practices, knowledge, attitudes, and barriers in the rural United States: A systematic review.
Journal of the American Pharmacists Association : JAPhA·2026
Personalizing an offer of pharmaceutical care services according to the expectations of youth and stakeholders in a youth rehabilitation centre: The POSER Study.
Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC·2026
Barriers and facilitators to antimicrobial stewardship in community pharmacy: A systematic review.
Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC·2026
The economics of community pharmacy in Canada. Part 2: A synthesis of the evidence on competitive strategies.
Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC·2026
Roles of the community pharmacist during the COVID-19 pandemic: An analysis of documents informing practice in Newfoundland and Labrador.
Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC·2026
Uptake of pharmacist services for common ambulatory conditions: A repeated cross-sectional evaluation of the Ontario Minor Ailment Services program.
Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC·2026